PT-141 (bremelanotide) therapy in Boise is available through Alturas Medical Weight Loss, a physician-led clinic located in nearby Meridian, Idaho.
PT-141 acts on melanocortin receptors in the brain involved in sexual desire and arousal and works differently from medications such as Viagra and Cialis, which primarily affect blood flow.
If you’ve experienced a persistent decrease in sexual desire that bothers you, a medical evaluation can help determine potential causes and whether PT-141 may be appropriate.
Treatment decisions are based on your medical history, medications, cardiovascular risk factors and, when appropriate, laboratory testing.
Low desire has many possible causes, so the first question is why it changed. These patterns are worth a medical evaluation, and PT-141 is one option that may come up.
The FDA label names uncontrolled hypertension and known cardiovascular disease as contraindications, so we screen for both. That screening is not optional here.
PT-141, also known as bremelanotide, is a peptide medication. The same active ingredient is sold as Vyleesi, which the FDA approved in 2019.
That approval is narrow. Vyleesi is approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder, usually shortened to HSDD. The term means low desire that causes real distress, not an occasional dip.
The label is equally clear about where it does not apply. It is not indicated for postmenopausal women or for men. It is also not for enhancing sexual performance.
Sildenafil (Viagra) and tadalafil (Cialis) are PDE5 inhibitors. They mainly address erectile function through effects on blood flow. PT-141 works differently.
It is a melanocortin receptor agonist, which means it acts on receptors in the brain. Those receptors sit in pathways tied to sexual motivation and arousal.
So the two approaches are not interchangeable. PT-141 acts through melanocortin receptors involved in sexual desire and arousal, rather than primarily targeting blood flow.
That distinction explains a common disappointment. If low blood flow is the real problem, PT-141 will not fix it. A different treatment will serve you better.
Working out which one you are dealing with is the entire point of the consultation.
The FDA approved Vyleesi based on two 24-week trials in about 1,250 premenopausal women with HSDD. Both measured sexual desire and how much low desire bothered patients.
Both differences were statistically significant, and both were modest. The trials found no significant difference in the number of satisfying sexual events. The prescribing information recommends stopping treatment after 8 weeks if symptoms have not improved.
PT-141 is not testosterone replacement and does not raise hormone levels. It will not resolve relationship conflict, depression or burnout, and it is not an erection pill taken on demand.
If a medication is contributing to low desire, reviewing that medication may be more appropriate than simply adding another prescription.
Low desire has a long list of causes. Thyroid disease, anemia, depression and SSRIs are among the common ones. Sleep loss, alcohol and chronic stress all pull in the same direction.
Treating the wrong cause costs money and delays the real answer. That is why we evaluate potential causes before deciding whether PT-141 is appropriate, including laboratory testing when clinically indicated.
What are the side effects of PT-141? The approved label lists several, with the rates below.
These figures come from the Vyleesi prescribing information.
Bars show the share of trial patients who reported each side effect.
Nausea was the most common side effect in the trials, reported by 40% of patients. It led 8% to stop treatment early, and 13% needed anti-nausea medication. For most, it improved with the second dose.
The label also describes a temporary rise in blood pressure. It peaks two to four hours after a dose and usually resolves within twelve hours.
That is why cardiovascular screening comes before a prescription rather than after. None of this makes PT-141 unsafe for everyone, but it does make the decision a clinical one.
Sources
Where these numbers come from
Last reviewed: October 2026
PT-141 is a prescription decision rather than a purchase, and we treat it that way.
Step by step
Every PT-141 evaluation follows the same six steps.
We review your symptoms and medical history.
We check what you already take, since many common drugs lower desire.
We check blood pressure and cardiovascular risk.
We order labs when clinically appropriate.
We decide together whether PT-141 is appropriate.
We go over dosing, side effects and follow-up.
Our medical clinic is in Meridian, about fifteen minutes from downtown Boise, and serves patients across the Treasure Valley.
Alturas Medical Weight Loss
1532 W Cayuse Creek Dr
Meridian, ID 83646
(208) 690-2040
PT-141 is one of several peptide therapies we offer. See our full peptide therapy program.
Dr. Ashley Southern, NMD
Physician and co-founder, Alturas Medical Weight Loss in Meridian, Idaho. Board-certified Naturopathic Medical Doctor prescribing and supervising every peptide protocol at the clinic.
Dr. Southern evaluates peptide therapy within the context of each patient’s medical history, medications, laboratory results and treatment goals. The goal is to determine whether a particular therapy is medically appropriate, rather than assuming every peptide is appropriate for every patient.
Credentials at a glance
Read more on the Meet Dr. Ashley Southern page, or book a free consultation.
PT-141 is one of several physician-prescribed peptides we offer at our Meridian clinic, near Boise. Every plan starts with a medical evaluation. Explore our full peptide therapy in Boise program or the related therapies below.
A GHRH analog studied for its effects on visceral adipose tissue and body composition.
An investigational peptide fragment of thymosin beta-4, studied primarily in laboratory research involving tissue repair and wound healing.
A peptide that has been studied, mostly in animal research, for tendon, ligament and gut-lining repair. Used in certain physician-supervised recovery protocols.
A combination of BPC-157 and TB-500 considered in physician-supervised recovery protocols.
Two peptides studied for their effects on growth hormone signaling, through different pathways. Human data on each is limited, and the combination has not been studied in humans.
Straight answers, sourced from the FDA label where one exists.
The active molecule is the same, bremelanotide. Vyleesi is the FDA-approved product. Compounded PT-141 is not the identical product.
No. The label states it is not indicated for men. Any use in men is off-label.
No. Viagra improves blood flow. PT-141 acts on brain receptors linked to desire.
The approved label directs dosing at least 45 minutes before anticipated sexual activity.
The label states that how long each dose works is unknown. It allows no more than one dose in 24 hours and does not recommend more than eight doses a month.
Nausea is the most common, reported in 40% of patients. Flushing and headache follow.
Yes, temporarily. The label describes a rise peaking two to four hours after a dose.
People with uncontrolled hypertension or known cardiovascular disease should not take it.
No. It is a peptide. It does not raise testosterone or other hormone levels.
Probably not. Erection problems often involve blood flow, which PT-141 does not address.
Our medical clinic is in Meridian at 1532 W Cayuse Creek Dr, about fifteen minutes from downtown Boise.
If a change in sexual desire is affecting your quality of life, a medical evaluation can identify possible causes and whether PT-141 is appropriate. Our medical clinic is in Meridian, serving Boise and the Treasure Valley.
